Abstract: Provided herein are biomarkers for cancer screening and monitoring. In particular, provided herein are lipid biomarkers for cancer diagnosis, prognosis, risk, and response to treatment.

Abstract: The present invention provides compositions, methods, and kits comprising PUFAs produced by microalgae, in particular omega-3 and/or omega-6 fatty acids produced by members of the genus Rhodomonas, in particular Rhodomonas salina and/or genetically engineered bacteria or co-cultures of microalgae and bacteria. The invention also provides compositions, methods, and kits comprising the PUFAs for the prophylactic and/or therapeutic treatment of a disease or condition, in particular a cardiovascular and/or inflammatory disease or condition.

Abstract: The present invention provides compositions, methods, and kits comprising PUFAs produced by microalgae, in particular omega-3 and/or omega-6 fatty acids produced by members of the genus Rhodomonas, in particular Rhodomonas salina. The invention also provides compositions, methods, and kits comprising the PUFAs for the prophylactic and/or therapeutic treatment of a disease or condition, in particular a cardiovascular and/or inflammatory disease or condition.

Abstract: The present invention provides compositions, methods, and kits comprising PUFAs produced by microalgae, in particular omega-3 and/or omega-6 fatty acids produced by members of the genus Rhodomonas, in particular Rhodomonas salina. The invention also provides compositions, methods, and kits comprising the PUFAs for the prophylactic and/or therapeutic treatment of a disease or condition, in particular a cardiovascular and/or inflammatory disease or condition.

Abstract: The present invention discloses processes of making a polyunsaturated fatty acid compositions, and compositions thereof. Thus, one method of making a polyunsaturated fatty acid compositions comprises at least 8% polyunsaturated fatty acids, the process comprising extracting the fatty acids from a microalgae, wherein the fatty acids can be (a) GLA in an amount of 1% to 10% of total fatty acids; (b) SDA in an amount of 5% to 50% of total fatty acids; (c) EPA in an amount of 2% to 30% of total fatty acids, and (d) DHA in an amount of 2% to 30% of total fatty acids, wherein a polyunsaturated fatty acid composition is produced comprising at least 8% polyunsaturated fatty acids. Additional processes of making polyunsaturated fatty acid compositions, animal feed additives, and animal products are disclosed and the compositions, feed additives and products thereof.

Abstract: Compositions for the treatment of symptoms of inflammatory disorders may include gamma-linolenic acid or dihomogammalinolenic acid, an inhibitor of ?5 desaturase, and optionally stearidonic acid or ?-3 arachidonic acid. Preferred formulations may be in the form of a good tasting, preferably milk or fruit based drink, or a dried powder. Compositions reduce inflammation and inhibit increase in serum arachidonic acid associated with gamma-linolenic acid.

Abstract: Compositions, dietary supplements and medical foods for the treatment of symptoms of inflammatory disorders may include gamma-linolenic acid or dihomogammalinolenic acid, an inhibitor of ?5 desaturase, and optionally stearidonic acid or ??3 arachidonic acid. Preferred formulations may be in the form of a good tasting, preferably milk or fruit based drink, or a dried powder. Compositions reduce inflammation and inhibit increase in serum arachidonic acid associated with gamma-linolenic acid. The compositions of the invention may also be used for the treatment of cytokine mediated disorders in patients in need thereof.